Pakdaman Kimia, Nikbakht Hossein-Ali, Esmaeilnia Shirvani Amin, Sahraian Saba, Shojaie Layla, Ebrahimi Pouyan
School of Medicine, Babol University of Medical Sciences, Babol, Iran.
Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Cancer Control. 2025 Jan-Dec;32:10732748251371479. doi: 10.1177/10732748251371479. Epub 2025 Aug 28.
IntroductionCancer is a significant worldwide health problem, and targeted drugs like Cabozantinib and Atezolizumab offer new therapeutic options. These drugs enhance patient survival by specifically targeting cancer cells while minimizing damage to healthy tissues. The current research investigates the effectiveness of employing the combination of Cabozantinib and Atezolizumab vs single-agent Cabozantinib.MethodsIn this study, we searched databases including PubMed/Medline, Scopus, Embase, Cochrane, and Web of Science up to the end of January 2025. The results were categorized into two groups: the intervention group (Cabozantinib plus Atezolizumab) and the control group (Cabozantinib monotherapy) in cancer patients. We evaluated variables such as efficacy outcomes, including Objective Response Rate (ORR) and Disease Control Rate (DCR), as well as adverse events (safety). Data analysis was performed using random-effects models, and Relative Risk (RR) was reported as the effect size.ResultsThree clinical trials were included in this study. Regarding efficacy outcomes, there was no statistically significant difference in ORR between the intervention group and the control group (RR = 1.11, 95% CI: 0.76-1.61). Similarly, DCR did not differ significantly between groups (RR = 0.98, 95% CI: 0.94-1.03). In terms of safety, the combination therapy was associated with a statistically significant reduction in four treatment-related adverse events: diarrhea (RR = 0.91, 95% CI: 0.83-0.99), nausea (RR = 0.79, 95% CI: 0.65-0.95), vomiting (RR = 0.70, 95% CI: 0.52-0.96), and hypokalemia (RR = 0.28, 95% CI: 0.19-0.40).ConclusionThe findings suggest that the combination of Cabozantinib and Atezolizumab does not offer significant improvement in treatment efficacy compared to Cabozantinib alone. However, the combination may be associated with a lower incidence of certain chemotherapy-related adverse events. These exploratory findings may inform future research on treatment strategies for patients who experience intolerance to Cabozantinib monotherapy.
引言 癌症是一个全球性的重大健康问题，卡博替尼和阿替利珠单抗等靶向药物提供了新的治疗选择。这些药物通过特异性靶向癌细胞，同时将对健康组织的损害降至最低，从而提高患者的生存率。目前的研究调查了联合使用卡博替尼和阿替利珠单抗与单独使用卡博替尼的有效性。 方法 在本研究中，我们检索了截至2025年1月底的PubMed/Medline、Scopus、Embase、Cochrane和Web of Science等数据库。结果分为两组：癌症患者的干预组（卡博替尼加阿替利珠单抗）和对照组（卡博替尼单药治疗）。我们评估了疗效结果（如客观缓解率（ORR）和疾病控制率（DCR））以及不良事件（安全性）等变量。使用随机效应模型进行数据分析，并报告相对风险（RR）作为效应大小。 结果 本研究纳入了三项临床试验。关于疗效结果，干预组和对照组之间的ORR没有统计学上的显著差异（RR = 1.11，95%CI：0.76 - 1.61）。同样，两组之间的DCR也没有显著差异（RR = 0.98，95%CI：0.94 - 1.03）。在安全性方面，联合治疗与四种治疗相关不良事件的统计学显著减少相关：腹泻（RR = 0.91，95%CI：0.83 - 0.99）、恶心（RR = 0.79，95%CI：0.65 - 0.95）、呕吐（RR = 0.70，95%CI：0.52 - 0.96）和低钾血症（RR = 0.28，95%CI：从0.19到0.40）。 结论 研究结果表明，与单独使用卡博替尼相比，联合使用卡博替尼和阿替利珠单抗在治疗疗效上没有显著改善。然而，联合治疗可能与某些化疗相关不良事件的发生率较低有关。这些探索性发现可能为未来对卡博替尼单药治疗不耐受的患者的治疗策略研究提供参考。
Cochrane Database Syst Rev. 2018-2-6
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2020-1-9
Psychopharmacol Bull. 2024-7-8
Cochrane Database Syst Rev. 2017-12-22
Cochrane Database Syst Rev. 2020-10-19
Cochrane Database Syst Rev. 2022-7-12
Crit Rev Oncol Hematol. 2024-4
Ther Adv Med Oncol. 2022-7-30
SAGE Open Med. 2021-8-12
Cancer Treat Rev. 2021-7
Zotero 插件
